Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Avalo Therapeutics (AVTX) over the last 10 years, with Q3 2025 value amounting to 0.56%.

  • Avalo Therapeutics' Return on Capital Employed rose 9100.0% to 0.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56%, marking a year-over-year increase of 9100.0%. This contributed to the annual value of 0.87% for FY2024, which is 3400.0% up from last year.
  • Per Avalo Therapeutics' latest filing, its Return on Capital Employed stood at 0.56% for Q3 2025, which was up 9100.0% from 0.49% recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Return on Capital Employed ranged from a high of 0.36% in Q1 2024 and a low of 2.92% during Q4 2022
  • Its 5-year average for Return on Capital Employed is 1.56%, with a median of 1.38% in 2023.
  • In the last 5 years, Avalo Therapeutics' Return on Capital Employed plummeted by -17100bps in 2022 and then soared by 25500bps in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Return on Capital Employed stood at 1.21% in 2021, then crashed by -141bps to 2.92% in 2022, then surged by 54bps to 1.33% in 2023, then soared by 56bps to 0.58% in 2024, then rose by 3bps to 0.56% in 2025.
  • Its Return on Capital Employed stands at 0.56% for Q3 2025, versus 0.49% for Q2 2025 and 0.36% for Q1 2025.